

Medical Oncology Coverage

Breast

- DCIS
- Invasive



Skin

- Melanoma
- Brain Metastasis
- Ocular



Gastrointestinal

- Anal
- Colon
- Rectal
- Gastric
- Esophageal
- GE Junction
- Pancreatic



Genitourinary

- Bladder
- Prostate
 - Adenocarcinoma
 - Small Cell
- Renal Cell
- Testicular
 - Seminoma
 - Non-seminoma
 - Sex cord stromal tumors



Head & Neck

- Hypopharynx
- Larynx
- Nasopharyngeal
- Occult Primary
- Oral Cavity
- Oropharynx
- Other Sites



Thoracic

- Mesothelioma
- NSCLC
- SCLC



Hematologic

- ITP
- CML
- MDS
- Multiple Myeloma

- Lymphomas:
 - Hodgkin's
 - Classic
 - Lymphocyte Predominant
 - Non-Hodgkin's
 - CLL
 - SLL
 - Diffuse Large B Cell
 - Follicular
 - High Grade
 - Mantle Cell
 - Marginal Zone
 - Mediastinal Large B Cell
 - Peripheral T Cell
 - Waldenstrom's/
Lymphoplasmacytic



Gynecologic

- Ovarian
- Uterine
 - Endometrioid Histology
 - Carcinosarcomas
 - Papillary Serous & Clear Cell Histology
 - Low Grade Endometrial Stromal Sarcoma
 - High Grade Undifferentiated/
Leiomyosarcoma



CNS

- Neuro-onc



Medical Oncology: On Pathway Rates

*Data for all customers
(excluding Private Label centers)
Medical Oncology
12 months ended 11/30/16*

| Disease | On-Pathway Rate |
|-------------------------------------|-----------------|
| Bladder | 76.0% |
| Breast | 87.0% |
| CML | 76.3% |
| Colorectal | 83.1% |
| Gastroesophageal | 73.1% |
| Head and Neck | 83.2% |
| Lymphoma and CLL | 77.6% |
| MDS | 85.8% |
| Melanoma | 86.3% |
| Mesothelioma | 59.2% |
| Multiple Myeloma | 78.4% |
| Non-Small Cell Lung | 79.1% |
| Ovarian | 68.4% |
| Pancreatic | 85.3% |
| Prostate | 86.4% |
| Renal Cell | 81.8% |
| Small Cell Lung | 81.4% |
| Testicular | 92.0% |
| Thyroid | 82.4% |
| Uterine | 76.9% |
| MedOnc Total | 82.2% |